Home » Doubts Build on Glaxo’s Anti-Aging Drugs
Doubts Build on Glaxo’s Anti-Aging Drugs
GlaxoSmithKline shocked the pharmaceutical industry in 2008 when it dropped $720 million
to buy Sirtris Pharmaceuticals, a biotechnology company working on drugs based on resveratrol, a chemical in red wine thought to combat the effects of
aging.
Forbes
Forbes
Upcoming Events
-
07May
-
14May
-
30May